Application of rhein or compound of rhein compound and arginine in preparation of medicine for treating diabetic complications

A technology for rhein and diabetes, which is applied to the application field of rhein or a compound of rhein compound and arginine in the preparation of a drug for treating diabetic complications, and can solve problems such as male sexual dysfunction.

Inactive Publication Date: 2011-11-30
ZHEJIANG CHINESE MEDICAL UNIV MEDICAL PIECES
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0026] The above inventions have not yet involved the use of rhein or rhein compound compounds to treat diabetic complications, including the treatment of diabetic cardiomyopathy; diabetic macroangiopathy; male sexual dysfunction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of rhein or compound of rhein compound and arginine in preparation of medicine for treating diabetic complications
  • Application of rhein or compound of rhein compound and arginine in preparation of medicine for treating diabetic complications
  • Application of rhein or compound of rhein compound and arginine in preparation of medicine for treating diabetic complications

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0094] Example 1, the compound of rhein and arginine (macroarginic acid) treats diabetic cardiomyopathy.

[0095] Diabetes was induced in rats by intraperitoneal injection of streptozotocin 65mg / kg. Blood sugar was as high as 25mM and maintained for 8 weeks. After 4 weeks, diabetic complications had appeared. The untreated group continued to develop. The treatment group was administered in the last 4 weeks (mg / kg, intragastric administration): positive drug aminoguanidine 100, and 3 doses of sarginic acid: 50 mg / kg, 100 mg / kg, 200 mg / kg. Although the untreated diabetic group did not receive medication, they controlled their food intake and were given dietary control treatments to obtain appropriate treatment.

[0096] Pharmacodynamic observation: It consists of macroscopic main pharmacodynamic indicators, expression of important bioactive molecules (mRNA, and protein) in diseased cells and other indicators.

[0097] Sarginic acid restored the above indicators to the normal...

Embodiment 2

[0099] Example 2, the treatment of diabetic macroangiopathy with sarginic acid. Basically the same as Example 1,

[0100] Diabetes was induced in rats by intraperitoneal injection of streptozotocin 65mg / kg. Blood sugar up to 25mM, maintained for 8 weeks. After 4 weeks, diabetic complications had appeared. The untreated group continued to develop. The treatment group was administered in the last 4 weeks (mg / kg, intragastric administration): positive drug aminoguanidine 100, and 3 doses of sarginic acid: 50 mg / kg, 100 mg / kg, 200 mg / kg. Although the untreated diabetic group did not receive medication, they controlled their food intake and were given dietary control treatments to obtain appropriate treatment.

[0101] The vasodilation function and NO bioavailability were restored after 4 weeks of treatment with sarginic acid and aminoguanidine. At the same time, the molecular biological targets abnormally expressed in the blood vessel wall are basically restored to the normal...

Embodiment 3

[0103] Example 3, the treatment of diabetic nephropathy with macrospermic acid.

[0104] Diabetes was induced in rats by intraperitoneal injection of streptozotocin 65mg / kg. Blood sugar was as high as 25mM and maintained for 8 weeks. After 4 weeks, diabetic complications had appeared. The untreated group continued to develop. The treatment group was administered in the last 4 weeks (mg / kg, intragastric administration): positive drug aminoguanidine 100, and 3 doses of sarginic acid: 50 mg / kg, 100 mg / kg, 200 mg / kg. Although the untreated diabetic group did not receive medication, they controlled their food intake and were given dietary control treatments to obtain appropriate treatment.

[0105]The trace protein in 24h urine of rats with diabetic nephropathy increased significantly, and the creatinine and non-protein nitrogen in blood increased, suggesting: diabetic nephropathy. At the same time, the molecular biological indicators: the gene and protein expression of PPARα i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
Login to view more

Abstract

The complex of rhein or rhein compound and arginine is used in the preparation of medicines for treating diabetic complications. The drug for the treatment of diabetic complications refers to the drug for the treatment of diabetic cardiomyopathy, the drug for the treatment of diabetic macrovascular disease, the drug for the treatment of diabetic nephropathy, the drug for the treatment of diabetic orchopathy, the drug for the treatment of diabetes complicated by male hypofunction, Or drugs for diabetic impotence. The new drug with good safety provided by the present invention; its drug effect will be better than traditional therapeutic drugs and treatment methods; it will open the paradigm of Chinese medicine supramolecular technology in the transformation of important active ingredients, and expand supramolecular technology in the research and development of innovative Chinese medicine drugs. application. The new drug is used for the treatment of diabetic complications, including: diabetic cardiomyopathy; diabetic macroangiopathy; diabetic nephropathy;

Description

technical field [0001] The invention relates to the application of rhein or the complex of rhein compounds and arginine in the preparation of medicines for treating diabetic complications. Background technique [0002] Diabetes and its complications are common and frequently-occurring diseases. The incidence of diabetes remains high, showing a trend of high incidence. The incidence rate in China is higher. Diabetes is mainly type II, which affects the middle-aged and elderly people. It is highly pathogenic and has become the cause of high mortality. Type II diabetes develops insulin resistance due to various pathogenic factors, and then develops into hyperglycemia, which damages the cells of vital organs and leads to complications. Mainly microvascular complications and macrovascular complications, involving diabetic cardiomyopathy, diabetic macrovascular complications, diabetic nephropathy, diabetic male hypofunction (testicular disease, impotence), diabetic retinopathy,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/205A61K31/192A61P3/10A61P9/00A61P13/12A61P15/00A61P15/10A61P27/02A61P25/00
Inventor 丛晓东戴德哉张云戴茵
Owner ZHEJIANG CHINESE MEDICAL UNIV MEDICAL PIECES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap